Mini-Focus: Platelet Responsiveness |
The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of ClopidogrelThe PRINC (Plavix Response in Coronary Intervention) Trial
Patrick Gladding, FRACP*,*,
Mark Webster, FRACP*,
Irene Zeng, MSc*,
Helen Farrell, BHSc*,
Jim Stewart, FRACP*,
Peter Ruygrok, FRACP*,
John Ormiston, FRACP*,
Seif El-Jack, FRACP*,
Guy Armstrong, FRACP*,
Patrick Kay, FRACP*,
Douglas Scott, FRACP*,
Arzu Gunes, MD, PhD ,
Marja-Liisa Dahl, MD, PhD
* Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden
* Reprint requests and correspondence: Dr. Patrick Gladding, Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92 024, Auckland 1030, New Zealand (Email: patrickg{at}adhb.govt.nz).
Objectives: This study evaluated the antiplatelet effect of a higher loading and maintenance dose regimen of clopidogrel and a possible drug interaction with verapamil.
Background: Clopidogrel loading doses above 600 mg have not resulted in more rapid or complete platelet inhibition. Higher maintenance dosages may be more effective than 75 mg/day.
Methods: A double-blind, randomized, placebo-controlled trial was undertaken in 60 patients undergoing percutaneous coronary intervention. All patients received clopidogrel 600 mg at the start of the procedure. Using a 2 x 2 design, patients were allocated to clopidogrel 600 mg given 2 h later or matching placebo, and to verapamil 5 mg intra-arterial or placebo. Platelet function was measured using the VerifyNow P2Y12 analyzer (Accumetrics Ltd., San Diego, California) at 2, 4, and 7 h. Patients were further randomized to receive a clopidogrel 75 or 150 mg once daily, with platelet function assessed after 1 week.
Results: Two hours after the second dose of clopidogrel or placebo, platelet inhibition was 42 ± 27% with clopidogrel, compared with 24 ± 22% with placebo (p = 0.0006). By 5 h after the second dose, platelet inhibition was 49 ± 30% with clopidogrel, compared with 29 ± 22% with placebo (p = 0.01). No drug interaction was seen with verapamil. A clopidogrel maintenance dosage of 150 mg daily for 1 week resulted in greater platelet inhibition than 75 mg daily (50 ± 28% vs. 29 ± 19%, p = 0.01).
Conclusions: In an unselected population undergoing percutaneous coronary intervention a clopidogrel 1,200-mg loading dose, given as two 600-mg doses 2 h apart, results in more rapid and complete platelet inhibition than a single 600-mg dose. A maintenance dosage of 150 mg daily produces greater platelet inhibition than 75 mg daily. (The PRINC trial; ACTRN12606000129583)
Key Words: angioplasty catheterization pharmacology platelets stents
|
Abbreviations and Acronyms
| | PCI = percutaneous coronary intervention | | PRU = platelet response unit | | RPFA = rapid platelet function analyzer |
|
Related Article
-
Searching for the Ceiling: New Reflections on the Disposition and Metabolism of Clopidogrel
- Neal S. Kleiman
J. Am. Coll. Cardiol. Intv. 2008 1: 628-630.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
P. Gladding, H. White, J. Voss, J. Ormiston, J. Stewart, P. Ruygrok, B. Bvaldivia, R. Baak, C. White, and M. Webster
Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer: A Dose-Escalation Study
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1095 - 1101.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J.,
August 2, 2009;
30(16):
1943 - 1963.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Gladding, M. Webster, I. Zeng, H. Farrell, J. Stewart, P. Ruygrok, J. Ormiston, S. El-Jack, G. Armstrong, P. Kay, et al.
The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
620 - 627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Kleiman
Searching for the Ceiling: New Reflections on the Disposition and Metabolism of Clopidogrel
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
628 - 630.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. B. King III and K. M. Momary
Thienopyridines: Time for Personalized Therapy?
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
718 - 719.
[Full Text]
[PDF]
|
 |
|
|